The American Society of Gene Therapy (ASGT) and Nature Publishing Group (NPG) announce a new publishing partnership
From January 2007, NPG will publish the Society's leading international title, Molecular Therapy (MT), and the journal will re-launch with a new look in print and online.
The journal's focus will not change and MT will continue to publish high-quality research and review articles.
David Williams will continue to serve as editor-in-chief and Robert Frederickson will remain as managing editor.
"In less than a decade, Molecular Therapy has become a leading journal for reporting advancements in molecular and cellular therapy, including gene therapy".
"We believe the move to NPG will enhance the appearance and impact of the journal and allow continued growth in the field," said Williams.
Molecular Therapy presents important, peer-reviewed studies on key issues in gene transfer, gene and cell therapies, experimental models for correction of genetic and acquired disease and clinical trials.
MT has become recognised as one of the most prestigious journals in the field.
MT is ranked in three ISI categories and has an impact factor of 5.204.
ASGT named NPG as its new publisher to help best meet its goals for developing Molecular Therapy.
"NPG is delighted to enter into this important partnership with the ASGT.
"The partnership fulfils our mission to provide the highest quality information to the global scientific community".
"We look forward to expanding the journal's readership and strengthening its position as the essential reference for all professionals related to gene therapy," said Annette Thomas, NPG's managing director, about the new partnership.
